Global Health

msf.org.uk - August 8, 2014

In a statement released today, the World Health Organization (WHO) declared that West Africa's Ebola epidemic is an "extraordinary event" and now constitutes an international health risk.

"A coordinated international response is deemed essential to stop and reverse the international spread of Ebola," the WHO said in a statement after a two-day meeting of its emergency committee on Ebola.

MSF reaction to WHO Ebola statement

In response, Dr Bart Janssens, Médecins Sans Frontières/Doctors Without Borders (MSF) Director of Operations said:

“Declaring Ebola an international public health emergency shows how seriously WHO is taking the current outbreak but statements won’t save lives

“Now we need this statement to translate into immediate action on the ground. For weeks, MSF has been repeating that a massive medical, epidemiological and public health response is desperately needed to saves lives and reverse the course of the epidemic.

“Lives are being lost because the response is too slow.

The World Health Organization has declared the Ebola outbreak in West Africa to be an international public health emergency that requires an extraordinary response to stop its spread.

It is the largest and longest outbreak ever recorded of Ebola, which has a death rate of about 50 per cent and has so far killed at least 932 people.

"Countries affected to date simply do not have the capacity to manage an outbreak of this size and complexity on their own," WHO chief, Dr. Margaret Chan, said at a news conference in Geneva. "I urge the international community to provide this support on the most urgent basis possible."

In the United States, the Centers for Disease Control and Prevention have already elevated their Ebola response to the highest level and have recommended against travelling to West Africa. On Thursday, CDC director Dr. Tom Frieden told a Congressional hearing that the current outbreak is set to sicken more people than all previous outbreaks of the disease combined.

c-span.org - August 7, 2014

The House Foreign Affairs Subcommittee on Africa, Global Health, Global Human Rights, and International Organizations held a hearing titled, “Combating the Ebola Threat.”

ZMapp TM is the result of a collaboration between Mapp Biopharmaceutical Inc. and LeafBio (San Diego, CA), Defyrus Inc. (Toronto, Canada), the U.S. government and the Public Health Agency of Canada (PHAC).

ZMapp TM is composed of three “humanized” monoclonal antibodies manufactured in plants, specifically Nicotiana.  It is an optimized cocktail combining the best components of MB-­‐003 (Mapp) and ZMAb (Defyrus/PHAC).

ZMapp TM was first identified as a drug candidate in January 2014 and has not yet been evaluated for safety in humans.  As such very little of the drug is currently available.  

Any decision to use an experimental drug in a patient would be a decision made by the treating physician under the regulatory guidelines of the FDA.

Mapp and its partners are cooperating with appropriate government agencies to increase production as quickly as possible.

CLICK HERE - ZMapp - Information Sheet (1 page .PDF file)

http://www.mappbio.com/